表柔比星联合奥沙利铂及替吉奥治疗晚期胃癌的近期疗效分析  

The Analysis of Short-Term Curative Effect of Epirubicin Combined with Oxaliplatin and S-1 in the Treatment of Advanced Gastric Cancer

作　　者：李绮云[1] 陈永锋[1] 林王美[1] 黄康龙[1] 

机构地区：[1]广东省农垦中心医院肿瘤内科,广东湛江524002

出　　处：《肿瘤基础与临床》2012年第4期294-296,共3页journal of basic and clinical oncology

摘　　要：目的观察表柔比星联合奥沙利铂及替吉奥治疗晚期胃癌的近期疗效及毒副反应。方法 11例经病理确诊的晚期胃癌患者接受化疗:表柔比星70 mg·m-2·d-1,静推,d1;奥沙利铂100 mg·m-2·d-1,静滴,d1;替吉奥80 mg·m-2·d-1,bid,口服,d1～14,每3周为1周期,化疗至少2周期后评价近期疗效和毒副反应。结果 11例患者中,CR 0例(0.00%),PR 5例(45.45%),SD 3例(27.27%),PD 3例(27.27%),有效率为45.45%,疾病控制率为72.73%。毒副反应主要是胃肠道反应、骨髓抑制,发生率分别为81.82%、72.73%,无治疗相关死亡。结论表柔比星联合奥沙利铂及替吉奥治疗晚期胃癌疗效较好,毒副反应可耐受。Objective To investigate the short-term curative effect and toxicities of epirubicin combined with oxaliplatin and S-1 in the treatment of advanced gastric cancer. Methods Eleven patients with advanced cancer con- firmed by pathology were administrated with the chemotherapy： epirubiein 70 mg·m^-2·d^-1 , iv, dl; oxaliplatin 100 mg·m^-2·d^-1 ,ivggt,dl ; S-1,80 mg·m^-2·d^-1 ,twice a day per oral from day 1 to days 14,every 3 weeks were 1 cycle, and the short-term curative effect and toxicities were evaluated after 2 cycles of chemotherapy. Results Of the 11 cases,CR was observed in the 0 case （0.00%）,PR in the 5 cases （45.45%）,SD in the 3 cases （27.27%） ,PD in the 3 cases （27.27%）, The overall response rate was 45.45%, the disease control rate was 72.73%. The most common toxicities were gastrointestinal reaction and myelosuppression, no chemotherapy-related death was observed. Conclusion The epirubicin combined with oxaliplatin and S-1 is effective for advanced gastric cancer, and the toxicities can be tolerated.

关 键 词：晚期胃癌 表柔比星 奥沙利铂 替吉奥 化疗 

分 类 号：R730.53[医药卫生—肿瘤] R735.2[医药卫生—临床医学]